⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24097821 | 1.00 | — | — | |
| SCHEMBL13806340 | 0.84 | — | — | |
| SCHEMBL11762385 | 0.78 | NOS3 (0.31) | — | |
| SCHEMBL18057675 | 0.73 | — | — | |
| SCHEMBL13741650 | 0.72 | — | — | |
| SCHEMBL17892081 | 0.71 | NOS3 (0.30) | — | |
| SCHEMBL30951928 | 0.69 | — | — | |
| SCHEMBL30951925 | 0.69 | — | — | |
| SCHEMBL18057680 | 0.68 | — | — | |
| SCHEMBL14225386 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260049080-A1 | WILD TYPE KIT INHIBITORS | BLUEPRINT MEDICINES CORP (US) | 2026-02-19 | — | — | US | disclosed |
| EP-4653050-A2 | CYCLOBUTYL DIHYDROQUINOLINE SULFONAMIDE COMPOUNDS | Amgen Inc. (US) | 2025-11-26 | — | — | EP | disclosed |
| EP-4637749-A2 | CBL-B MODULATORS AND USES THEREOF | Nimbus Clio, Inc. (US) | 2025-10-29 | — | — | EP | disclosed |
| US-12448379-B2 | Wild type kit inhibitors | BLUEPRINT MEDICINES CORPORATION (US) | 2025-10-21 | — | — | US | disclosed |
| US-12428425-B2 | Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use | AMGEN INC. (US) | 2025-09-30 | — | — | US | disclosed |
| EP-4165024-B1 | CYCLOBUTYL DIHYDROQUINOLINE SULFONAMIDE COMPOUNDS | AMGEN INC (US) | 2025-07-16 | — | — | EP | disclosed |
| US-20250171425-A1 | USES OF CYCLOBUTYL DIHYDROQUINOLINE SULFONAMIDE COMPOUNDS | AMGEN INC. | 2025-05-29 | — | — | US | disclosed |
| CN-119735588-A | Cyclobutyl dihydroquinolines sulfonamide compounds | 美国安进公司 | 2025-04-01 | — | — | CN | disclosed |
| US-20250099448-A1 | HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2025-03-27 | — | — | US | disclosed |
| US-12240839-B2 | Cyclobutyl dihydroquinoline sulfonamide compounds | AMGEN INC. (US) | 2025-03-04 | — | — | US | disclosed |
| US-11608344-B2 | Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use | AMGEN INC. (US) | 2023-03-21 | — | — | US | disclosed |
| WO-2023023202-A1 | STEREOSELECTIVE PREPARATION OF TRANS HALO CYCLOBUTANE | AMGEN INC. (US) | 2023-02-23 | — | — | WO | disclosed |
| CN-115697971-A | Cyclobutyldihydroquinoline sulfonamide compound | 美国安进公司 | 2023-02-03 | — | — | CN | disclosed |
| US-20230002390-A1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | AMGEN INC. | 2023-01-05 | — | — | US | disclosed |
| WO-2022236272-A2 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | VIGIL NEUROSCIENCE, INC. (US) | 2022-11-10 | — | — | WO | disclosed |
| US-20220306604-A1 | CYCLOBUTYL DIHYDROQUINOLINE SULFONAMIDE COMPOUNDS | AMGEN INC. (US) | 2022-09-29 | — | — | US | disclosed |
| US-20220098176-A1 | HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2022-03-31 | — | — | US | disclosed |
| US-20210387978-A1 | CYCLOBUTYL DIHYDROQUINOLINE SULFONAMIDE COMPOUNDS | AMGEN INC. (US) | 2021-12-16 | — | — | US | disclosed |
| WO-2021252820-A1 | CYCLOBUTYL DIHYDROQUINOLINE SULFONAMIDE COMPOUNDS | AMGEN INC. (US) | 2021-12-16 | — | — | WO | disclosed |
| WO-2021226629-A1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | AMGEN INC. (US) | 2021-11-11 | — | — | WO | disclosed |